Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: Early outcomes

International Journal of Urology

Volumn 18, Issue 6, 2011, Pages 483-487

  Okamura, Kikuo ^a   Nojiri, Yoshikatsu ^a   Ameda, Kaname ^c   Namima, Takashige ^d   Suzuki, Masahito ^e   Inoue, Katsumi ^f   Ogawa, Takatoshi ^g   Gotoh, Momokazu ^b   Homma, Yukio ^h  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Department of Urology   (Japan)

^d TOHOKU ROSAI HOSPITAL   (Japan)

^e TOKYO UNIVERSITY OF SCIENCE   (Japan)

^f SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^g Kainan Municipal Hospital   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

Botulinum toxin A; Non neurogenic overactive bladder; Short term outcome

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER EMPTYING; BLADDER MUCOSA; CLINICAL ARTICLE; DETRUSOR MUSCLE; DISEASE SEVERITY; DIZZINESS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEADACHE; HEMATURIA; HUMAN; JAPAN; MALE; MICTURITION DISORDER; MUSCLE WEAKNESS; OVERACTIVE BLADDER; PARESTHESIA; PATIENT ASSESSMENT; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QUESTIONNAIRE; REFRACTORY NONNEUROGENIC OVERACTIVE BLADDER; SCORING SYSTEM; SIDE EFFECT; SWEATING; TINNITUS; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS;

AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 79956290413     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02768.x     Document Type: Article

References (20)

1. Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005; 96: 1314-18.
2. Schimpf MO, Patel M, O'Sullivan DM, Tulikangas PK. Difference in quality of life in women with urge urinary incontinence compared to women with stress urinary incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2009; 20: 781-6.
3. Nabi G, Cody JD, Ellis G etal. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 2006; (4): CD003781.
4. Ubee SS, Manikandan R, Singh G. Medical management of overactive bladder. Indian J. Urol. 2010; 26: 270-8.
5. Kay GG, Abou-Donia MB, Messer WS Jr etal. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J. Am. Geriatr. Soc. 2005; 53: 2195-201.
6. Schurch B, Stohrer M, Kramer G etal. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. 2000; 164: 692-7.
7. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 2005; 66: 94-8.
8. Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005; 96: 848-52.
9. Schmid DM, Sauermann P, Werner M etal. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J. Urol. 2006; 176: 177-85.
10. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 2007; 177: 2231-6.
11. Brubaker L, Richter HE, Visco A etal. Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 2008; 180: 217-22.
12. Cohen BL, Barboglio P, Rodriguez D, Gousse AE. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol. Urodyn. 2009; 28: 205-8.
13. Watanabe T, Saito M, Hirakawa S, Miyagawa I. The effect of botulinum toxin injection into the bladder for overactive bladder: two case. Jpn J. Urol. 2005; 96: 511-14 (in Japanese).
14. Miyagawa I, Watanabe T, Isoyama T, Honda M etal. Experience with injections of botulinum toxin type A into the detrusor muscle. Aktuelle Urol. 2010; 41: S24-6.
15. Homma Y, Yoshida M, Seki N etal. Symptom assessment tool for overactive bladder syndrome - overactive bladder symptom score. Urology 2006; 68: 318-23.
16. Gotoh M, Homma Y, Funahashi Y etal. Psychometric validation of the Japanese version of the International Consultation on Incontinence Questionnaire-Short Form. Int. J. Urol. 2009; 16: 303-6.
17. Okamura K, Nojiri Y, Osuga Y, Tange C. Psychometric analysis of international prostate symptom score for female lower urinary tract symptoms. Urology 2009; 73: 1199-202.
18. Flynn MK, Amundsen CL, Perevich M etal. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J. Urol. 2009; 181: 2608-15.
19. Dmochowski R, Chapple C, Nitti VW etal. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J. Urol. 2010; 184: 2416-22.
20. Anger JT, Weinberg A, Suttorp MJ etal. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J. Urol. 2010; 183: 2258-64.